drugset
drugset / Trial / NCT04654390

The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus

NCT04654390 ↗

Phase 3 Completed 270 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of DWP16001 compared to active drug in the treatment of type 2 diabetes mellitus.

Timeline

Start
2020-12-30
Primary completion
2021-12-17
Completion
2021-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Enavogliflozin Small molecule — Oral

Indications

type 2 diabetes mellitus